针对NSCLC的新辅助免疫疗法:优越的组合策略,最佳的治疗周期和来自贝叶斯元分析的预测指标
Yubingxue Liu1, Jianlin Long2, Huan Deng2
1Department of Health Examination and Oncology Screening Center, Chongqing University Cancer Hospital and Chongqing Cancer Institute, Chongqing, China.
Frontiers in immunology
|April 11, 2025
概括
新辅助性免疫检查点抑制剂 (ICI) 与抗血管生成剂相结合,对可切除非小细胞肺癌 (NSCLC) 有效. 三个周期提供最佳疗效,主要病理反应 (MPR) 是无事件生存 (EFS) 的强有力的预测指标.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 胸部外科手术 胸部外科手术
背景情况:
- 新辅助性免疫检查点抑制剂 (ICI) 对可切除的非小细胞肺癌 (NSCLC) 显示出希望.
- 针对长期结果的最佳组合策略,治疗周期和预测生物标志物需要进一步研究.
- 这项研究解决了对可切除NSCLC的基于ICI的新辅助疗法的明确性需求.
研究的目的:
- 评估各种基于ICI的新辅助疗法在可切除NSCLC中的疗效.
- 为了确定新辅助免疫化学疗法的最佳治疗周期.
- 评估病理完整反应 (pCR) 和重大病理反应 (MPR) 对于无事件生存 (EFS) 的预后价值.
主要方法:
- 在PubMed,EMBASE,Cochrane CENTRAL和Web of Science中进行系统的文献搜索,直到2024年10月.
- 贝叶斯模型用于分析治疗疗效,最佳免疫化疗周期和MPR/pCR的预后值.
- 包括来自34项研究的数据 (32个单臂,8个RCT) 涉及4,593名患者.
主要成果:
- 与抗血管生成药物结合的免疫化学疗法显示出最高的疗效,显著改善了MPR和pCR.
- 在新辅助免疫化学疗法的3个循环之后,没有发现显著的疗效改善.
- 无论是MPR还是pCR都强烈预测了EFS;MPR与事件风险的负相关性更强 (日志HR: -2.110) 比pCR (日志HR: -1.665).
结论:
- 使用抗血管生成剂的新辅助免疫化学疗法是对可切除NSCLC的高度有效策略.
- 新辅助性免疫化学疗法的三个周期似乎是最大限度地提高疗效的最佳选择.
- MPR和pCR是EFS的有价值的预后指标,MPR显示出卓越的预测能力.
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
01:27Tumor Immunotherapy
406
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
406
01:30Cancer Vaccines
260
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
260
01:21Cancer Survival Analysis
308
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
308